Edition:
United Kingdom

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

103.50EUR
9:00am BST
Change (% chg)

€-0.10 (-0.10%)
Prev Close
€103.60
Open
€103.60
Day's High
€103.70
Day's Low
€103.10
Volume
7,567
Avg. Vol
54,067
52-wk High
€107.20
52-wk Low
€50.13

Chart for

About

Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and... (more)

Overall

Beta: 0.51
Market Cap(Mil.): €5,404.52
Shares Outstanding(Mil.): 92.18
Dividend: 0.42
Yield (%): 0.72

Financials

  STDM.PA Industry Sector
P/E (TTM): 34.49 32.29 32.76
EPS (TTM): 1.70 -- --
ROI: 18.12 13.92 14.61
ROE: 21.44 16.77 16.33

BRIEF-Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros

* IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS.

24 Apr 2018

BRIEF-Sartorius Stedim Biotech And Penn State University Entered Into Collaborative Partnership

* SARTORIUS STEDIM BIOTECH AND PENN STATE UNIVERSITY ENTERED INTO COLLABORATIVE PARTNERSHIP TO ADVANCE MULTIDISCIPLINARY TEACHING AND RESEARCH IN BIOTECHNOLOGY Source text : https://bit.ly/2qygOm0 Further company coverage: (Gdynia Newsroom)

16 Apr 2018

BRIEF-Sartorius Stedim Biotech Launches New Ambr 250 High Throughput Bioreactor System

* LAUNCHES NEW AMBR 250 HIGH THROUGHPUT BIOREACTOR SYSTEM FOR PERFUSION CULTURE Source text: http://bit.ly/2FKA8C8 Further company coverage: (Gdynia Newsroom:)

14 Mar 2018

BRIEF-Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%

* SARTORIUS STEDIM BIOTECH TARGETS CONTINUED PROFITABLE GROWTH - SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025

21 Feb 2018

Earnings vs. Estimates